Deals & Corporate Governance

  • October 16, 2026

    Taxation With Representation: Freshfields, Morgan Lewis

    In this week's Taxation With Representation, Penske Automotive Group Inc. agrees to be taken private by Motown Acquisition Corp., a GTCR-led group of private investment firms acquires software firm CCC Intelligent Solutions Holdings Inc. and a Steris PLC subsidiary buys specialty surgical products business Xodus Medical Inc.

  • October 14, 2026

    10th Circ. Backs Asset Freeze In SEC Case Against Biotech

    The Tenth Circuit on Wednesday backed a lower court's order freezing a biotech firm's assets in a suit brought by the U.S. Securities and Exchange Commission accusing the company and its founders of misappropriating roughly $9 million.

  • October 14, 2026

    NC Health Plan Can't Block Atrium's Cost-Sharing Program

    Atrium Health can move forward with a program to offer lower healthcare costs to members of North Carolina's state health plan, a state court judge ruled, handing a loss to the state treasurer in his lawsuit claiming Atrium's program will ultimately saddle the plan with more debt.

  • October 14, 2026

    Sanofi Agrees Not To Disparage Rival's Flu Vaccine

    European enforcers have accepted commitments from Sanofi over concerns that it blocked competition from a rival flu vaccine for vulnerable patients by making disparaging statements to healthcare professionals in Germany and France.

  • October 13, 2026

    Liquidia Settles United Therapeutics Suits With $380.7M Deal

    Liquidia will pay out $380.7 million as part of a settlement agreement with United Therapeutics Corp. that resolves six lawsuits between the pharmaceutical companies, Liquidia announced Tuesday, saying patients will continue to have access to its Yutrepia lung disease treatment that was central to litigation.

  • October 13, 2026

    FTC Wants Shkreli Sanctioned Over Pharma Industry Ban

    The Federal Trade Commission and seven states asked a New York federal judge Tuesday to hold Martin Shkreli in contempt for violating a court order banning him from the pharmaceutical industry by trading in industry stocks and broadcasting opinions about the business since he was released from prison in 2022.

  • October 13, 2026

    Facing Mandatory Fed Price Program, Pharma Goes To Court

    The first major lawsuit focused on "most favored nation" drug pricing efforts hit the courts last week. A bigger fight might be ahead as more mandatory programs emerge.

  • October 13, 2026

    Jones Day, Morgan Lewis Guide $2.1B Steris-Xodus Deal

    Steris PLC has agreed to acquire specialty surgical products business Xodus Medical Inc. and some affiliates for $2.1 billion, with Jones Day advising Steris and Morgan Lewis & Bockius LLP representing Xodus.

  • October 13, 2026

    Health Co. Mirra-Access Hits Ch. 11 To Deal With $400M Loan

    Healthcare company Mirra-Access is seeking Chapter 11 protection in a Florida bankruptcy court with more than $100 million in debt and plans to restructure a loan facility with a firm tied to Franklin Templeton.

  • October 13, 2026

    Dentons Adds K&L Gates Lawyer To Healthcare Practice In DC

    Dentons has hired a former K&L Gates LLP counsel as a partner in its Washington, D.C., office, where he will advise pharmaceutical, biotechnology and medical device companies on a range of matters related to regulatory and transactional oversight, the firm announced.

  • October 09, 2026

    TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M

    Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings.

  • October 08, 2026

    Taro Pharma Says MDL Deal Bars States' Duplicative Claims

    Taro Pharmaceuticals USA asked a Connecticut federal judge to toss generic-drug price-fixing claims brought by a coalition of states on behalf of consumers that are duplicative of claims the consumers have already resolved through settlements in separate multidistrict litigation.

  • October 08, 2026

    Mayne, Ascend Cut $1M Generic Price-Fixing Deal With States

    Ascend Laboratories, Mayne Pharma and Citron Pharma asked a Connecticut federal judge Thursday to sign off on a settlement with a coalition of states resolving claims the companies were involved in an illegal conspiracy to fix prices and suppress competition for generic drugs in the United States. 

  • October 08, 2026

    Genesis Healthcare Gets OK For Amended $1B Asset Sale

    A Texas bankruptcy judge Thursday approved the sale of Genesis Healthcare's 175 care facilities after being told that the debtor had reached an amended deal with the buyer that will add $15 million in cash to the $1 billion Genesis was already slated to receive.

  • October 08, 2026

    Viatris To Buy Pacira BioSciences For $1.65B

    Viatris has agreed to acquire non-opioid pain treatment maker Pacira BioSciences for $1.65 billion, with Cravath Swaine & Moore LLP advising Viatris and Ashurst Perkins Coie representing Pacira, the companies said Thursday.

  • October 07, 2026

    3rd Circ. Upends Sandoz's $61.6M Award Against UTC

    A Third Circuit panel on Wednesday erased Sandoz Inc.'s $61.6 million award in a breach of contract case against United Therapeutics Corp., in a decision that sidesteps the major pharmaceutical company's request to reinstate a $137.2 million damages calculation that had been halved by the trial judge.

  • October 07, 2026

    NC Hospital Accuses Blue Cross Of Refusing Covered Claims

    Blue Cross and Blue Shield of North Carolina is refusing to pay or underpaying for covered services on behalf of its members, a hospital in the Tar Heel State has alleged in a new complaint accusing the insurer of violating the parties' network participation agreement.

  • October 07, 2026

    Immunomedics Founder Says Deal Triggered $365M Pay Claim

    The founder of Immunomedics urged Delaware's highest court Wednesday to reinstate his roughly $365 million compensation claim against the biotechnology company, alleging Gilead Sciences Inc. became an "affiliate" when it bought Immunomedics for $21 billion and that his employment agreement therefore reaches Gilead's revenues.

  • October 07, 2026

    Kirkland-Led Sheridan Secures $1.345B For 2 Latest Funds

    Kirkland & Ellis LLP-advised Sheridan Capital Partners on Wednesday revealed that it raised $1.345 billion across two new funds, which will be used to invest across various healthcare sectors.

  • October 06, 2026

    NC Biz Court Bulletin: Monopoly Suit Setback, Historic Deal

    The North Carolina Business Court rounded the corner into fall with a setback for residents in an antitrust class action, a historic settlement in "forever chemical" contamination litigation and a raft of new restrictive covenant complaints.

  • October 06, 2026

    Dentists Can't Avoid Delta Dental MDL

    The Judicial Panel on Multidistrict Litigation held that dentists pursuing five new lawsuits against Delta Dental and its network cannot avoid the Illinois federal court MDL accusing the insurance giant of anticompetitively carving up markets and driving down reimbursements.

  • October 06, 2026

    4 Firms Advise On $5.8B Option Care Health Take-Private Deal

    Private equity firm Clayton Dubilier & Rice and healthcare company McKesson Corp. said Tuesday they have agreed to acquire Option Care Health for $5.8 billion, taking the largest U.S. independent provider of home and alternate-site infusion services private.

  • October 05, 2026

    Shionogi To Buy Texas Biotech IntraBio In $2B Deal

    Japanese drugmaker Shionogi & Co. said Monday it has agreed to acquire Austin, Texas-based biotech IntraBio Inc. for $2 billion, with Cleary Gottlieb Steen & Hamilton LLP advising Shionogi and Kirkland & Ellis LLP and DLA Piper representing IntraBio.

  • October 05, 2026

    Drug Discounter's $48M Arbitration Award Tossed For Fraud

    A Florida federal judge vacated a $48 million arbitration award won by a drug discounter for unpaid commissions for pharmacy claims under an agreement with an Illinois-based pharmacy benefit company, finding the award had been procured by fraud.

  • October 05, 2026

    Justices Want SG's View On 3 Antitrust Cases

    The U.S. Supreme Court on Monday called for the solicitor general's view in antitrust cases involving hard drive component prices, allergy testing and treatment, and insulin products sold through a drug discount program.

Expert Analysis

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Risk Reduction Lessons For PE Firms From PowerSchool Suit

    Author Photo

    A California federal court's recent orders allowing claims against Bain Capital to proceed based on a data breach at its subsidiary PowerSchool indicate that private equity firms need to strategically approach acquisition activities to avoid cybersecurity risks, say attorneys at Womble Bond.

  • PowerSchool Data Breach Ruling Underscores PE Liability

    Author Photo

    The recent California federal court decision in PowerSchool, where Bain Capital was unable to dismiss claims relating to a data breach based in part on Bain's preinvestment activities, is an important addition to the line of cases addressing investor liability for acts of a portfolio company, says Mark Kelley at MoloLamken.

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Bid Protest Spotlight: Evidence, Tailored Talks, Materiality

    Author Photo

    In this month's bid protest roundup, Brian Doll at MoFo delves into three recent decisions from the Government Accountability Office about the evidentiary standards necessary to sustain a protest, discussions tailored to individual proposals, and misrepresentation claims involving factors irrelevant to the agency's decision.

  • Senior Housing Demands A Distinct Dealmaking Playbook

    Author Photo

    An aging population and evolving state regulations underscore a critical reality that senior housing assets can undergo operational or compliance shifts during dealmaking, highlighting the need for unique contractual safeguards like expanded disclosures, anchored notice obligations, and targeted closing conditions and remedies, say attorneys at Goodwin.

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.